Chronic myelogenous leukemia historical perspective
|
Chronic myelogenous leukemia Microchapters |
|
Differentiating Chronic myelogenous leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic myelogenous leukemia historical perspective On the Web |
|
American Roentgen Ray Society Images of Chronic myelogenous leukemia historical perspective |
|
Chronic myelogenous leukemia historical perspective in the news |
|
Blogs on Chronic myelogenous leukemia historical perspective |
|
Directions to Hospitals Treating Chronic myelogenous leukemia |
|
Risk calculators and risk factors for Chronic myelogenous leukemia historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
In the 1840s, the first cases of chronic myelogenous leukemia (splenomegaly with high leukocyte count) was reported in France, Germany, and Scotland. In 1960, the association of Philadelphia chromosome with the pathogenesis of chronic myelogenous leukemia was first discovered. In 1973, (9;22) translocation was first discovered. Definition of the breakpoint cluster region on chromosome 22 was first reported in 1984 and the demonstration of the BCR-ABL transcript in CML was first discovered in 1985. From 1980 onwards allogeneic stem cell transplantation (SCT) became the treatment of choice for eligible patients. In 1998, the era of tyrosine kinase inhibitors (TKI) began.
Historical Perspective
Important dates in chronic myelogenous leukemia:
- In the 1840s, the first cases of chronic myelogenous leukemia was first reported.
- In 1960, Philadelphia chromosome was first discovered by Peter Nowell and David Hungerford.
- In 1973, (9;22) translocation was first discovered.
- From 1980, allogeneic stem cell transplantation (SCT) became the treatment of choice for eligible patients.
- In 1984, definition of the breakpoint cluster region on chromosome 22 was first reported.
- In 1985, the BCR-ABL transcript was first discovered.
- In 1998, the era of tyrosine kinase inhibitors (TKI) began.